Phenomics & Genomics of Clozapine Pharmacotherapy - Current Users

Recruiting

• Conditions: psychosis; psychotic disorders; 10039628

• Registration Number: NL-OMON50518
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 2778

Inclusion Criteria

-he/she currently uses clozapine or has used clozapine
-he/she has received a diagnosis of schizophrenia, schizophreniform,
schizoaffective disorder or psychotic disorder NOS (DSM IV)/(un)specified
schizspectrum or other psychotic disorder (DSM 5).
-his/her age must be >=18 years old
-he/she must be able to speak and read the Dutch language
-he/she must understand the information provided about the study and understand
the consequences of participating and express a willingness to participate.
This estimation is done by the treating physician during the informed consent
procedure.

Exclusion Criteria

- Involuntarily admission (unless allowed by local law)
- when the treating physician doubts if the patient understands the
information/consequences of participation or the willingness to participate
- Patients with Parkinson*s disease

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To assess whether the genetic architecture of this severe SCZ phenotype differs<br /><br>from the broad DSM-based SCZ phenotype.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To detect genetic associations with the current severe SCZ phenotype in healthy<br /><br>participants (case-control comparison)</p><br>